Premium
The pharmacokinetics of ciclazindol (Wy 23409) in human volunteers.
Author(s) -
Swaisland AJ,
Franklin RA,
Southgate PJ,
Coleman AJ
Publication year - 1977
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.1977.tb00668.x
Subject(s) - pharmacokinetics , dosing , pharmacology , urine , drug , half life , excretion , metabolism , oral administration , drug metabolism , feces , chemistry , medicine , biology , paleontology
1. The pharmacokinetics and metabolism of ciclazindol, a potential anti‐ depressant drug, have been studied after oral administration of the compound to male and female volunteers. 2. The mean +/‐ S.E. mean maximum plasma concentration of the unchanged drug was 422 +/‐ 31 ng/ml. This level was seen between 2 and 4 h after dosing. 3. Elimination of the ciclazindol from plasma was apparently monexponential with a half‐life of approximately 32 h. A large proportion of the drug‐related substances in the plasma was unchanged drug. 4. Excretion of radioactivity took place predominantly via the renal route, less than 15% of the dose being recovered in the faeces. The urinary elimination process was apparently monoexponential with a half‐life of 28 h. 5. Daily dosing with ciclazindol for 3 weeks did not appear to induce the enzymes of its own metabolism.